<DOC>
	<DOCNO>NCT01105598</DOCNO>
	<brief_summary>This Phase 1 , double-blind ( sponsor open ) study assess safety , tolerability , pharmacokinetics pharmacodynamics multiple dos ETC-1002 give subject mild dyslipidemia .</brief_summary>
	<brief_title>A Multiple Ascending Dose Study ETC-1002 Subjects With Mild Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Healthy male female subject nonchild bear potential determined medical history , physical examination , vital sign , ECG , clinical laboratory measurement Fasting low density lipoproteincholesterol ( LDLC ) 100160 mg/dL Fasting triglyceride ( TG ) 100350 mg/dL ( Cohort 5 ) Body Mass Index ( BMI ) 1832 kg/m2 ( Cohort 1 4 ) 1836 ( Cohort 5 ) body weight &gt; 50 kg Clinically significant disease require physician 's care and/or would interfere study evaluation Alanine aminotransferase ( ALT ) aspartate amino transferase ( AST ) &gt; 1.2 x ULN ; serum creatinine &gt; ULN ; hemoglobin &lt; 12.0 g/dL ; clinical lab test ( exception ALT , AST , serum creatinine hemoglobin ) outside normal protocol specify limit determine Investigator clinically significant Use tobacco tobacco product Use prescription nonprescription drug , vitamin , dietary supplement within 14 day prior randomization exception lipid regulating drug supplement contain niacin &gt; 500 mg/day fish oil use 3 month prior randomization Other exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>